These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F Front Immunol; 2018; 9():14. PubMed ID: 29403496 [TBL] [Abstract][Full Text] [Related]
6. TNF-R1, an immune checkpoint in melanoma? Bertrand F; Colacios C; Ségui B Genes Cancer; 2015 Sep; 6(9-10):369-70. PubMed ID: 26622939 [No Abstract] [Full Text] [Related]
7. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
8. Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8 Kobayashi T; Oishi K; Okamura A; Maeda S; Komuro A; Hamaguchi Y; Fujimoto M; Takehara K; Matsushita T J Invest Dermatol; 2019 Jul; 139(7):1535-1544.e1. PubMed ID: 30836062 [TBL] [Abstract][Full Text] [Related]
10. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991 [No Abstract] [Full Text] [Related]